Septerna, Inc.

Septerna, Inc. (SEPN) priced its initial public offering on Oct 25, 2024 at $18.00 per share, raising $288M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $756.1M. J.P. Morgan was lead-left underwriter, joined by TD Cowen, Cantor and Wells Fargo. Goodwin Procter advised the company and Cooley advised the underwriters.

Septerna, Inc. is a clinical-stage biotechnology company discovering oral small molecule drugs aimed at G protein-coupled receptors (GPCRs) using its Native Complex Platform. Its pipeline initially targets endocrinology, immunology and inflammation, and metabolic diseases.

Status

IPO

Ticker

SEPN

Exchange

Nasdaq Global Market

Priced

Oct 25, 2024

IPO price

$18.00

Raised

$288M

Market cap at IPO price

$756.1M

First filed

Oct 2, 2024

Underwriters

J.P. Morgan, TD Cowen, Cantor and Wells Fargo

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.